Clinical Trial Detail

NCT ID NCT02576509
Title A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

hepatocellular carcinoma

Therapies

Nivolumab

Sorafenib

Age Groups: adult

No variant requirements are available.